1	Expression	expression	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	c-fos	c-fos	_	_	_	_	_	_	_
4	correlates	correlate	_	_	_	_	_	_	_
5	with	with	_	_	_	_	_	_	_
6	IFN-alpha	IFN-alpha	_	_	_	_	_	_	_
7	responsiveness	responsiveness	_	_	_	_	_	_	_
8	in	in	_	_	_	_	_	_	_
9	Philadelphia	Philadelphia	_	_	_	_	_	_	_
10	chromosome	chromosome	_	_	_	_	_	_	_
11	positive	positive	_	_	_	_	_	_	_
12	chronic	chronic	_	_	_	_	_	_	_
13	myelogenous	myelogenous	_	_	_	_	_	_	_
14	leukemia	leukemia	_	_	_	_	_	_	_
15	.	.	_	_	_	_	_	_	_

1	This	this	_	_	_	_	_	_	_
2	study	study	_	_	_	_	_	_	_
3	evaluates	evaluate	_	_	_	_	_	_	_
4	(	(	_	_	_	_	_	_	_
5	i	i	_	_	_	_	_	_	_
6	)	)	_	_	_	_	_	_	_
7	constitutive	constitutive	_	_	_	_	_	_	_
8	levels	level	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	oncogene	oncogene	_	_	_	_	_	_	_
11	and	and	_	_	_	_	_	_	_
12	p53	p53	_	_	_	_	_	_	_
13	transcripts	transcript	_	_	_	_	_	_	_
14	in	in	_	_	_	_	_	_	_
15	chronic	chronic	_	_	_	_	_	_	_
16	phase	phase	_	_	_	_	_	_	_
17	CML	CML	_	_	_	_	_	_	_
18	patients	patient	_	_	_	_	_	_	_
19	and	and	_	_	_	_	_	_	_
20	(	(	_	_	_	_	_	_	_
21	ii	ii	_	_	_	_	_	_	_
22	)	)	_	_	_	_	_	_	_
23	their	their	_	_	_	_	_	_	_
24	modulations	modulation	_	_	_	_	_	_	_
25	subsequent	subsequent	_	_	_	_	_	_	_
26	to	to	_	_	_	_	_	_	_
27	in	in	_	_	_	_	_	_	_
28	vivo	vivo	_	_	_	_	_	_	_
29	therapy	therapy	_	_	_	_	_	_	_
30	with	with	_	_	_	_	_	_	_
31	rIFN-alpha	rifn-alpha	_	_	_	_	_	_	_
32	2c.	2c.	_	_	_	_	_	_	_
33	Peripheral	peripheral	_	_	_	_	_	_	_
34	blood	blood	_	_	_	_	_	_	_
35	mononuclear	mononuclear	_	_	_	_	_	_	_
36	cells	cell	_	_	_	_	_	_	_
37	(	(	_	_	_	_	_	_	_
38	pbmc	pbmc	_	_	_	_	_	_	_
39	)	)	_	_	_	_	_	_	_
40	and	and	_	_	_	_	_	_	_
41	bone	bone	_	_	_	_	_	_	_
42	marrow	marrow	_	_	_	_	_	_	_
43	cells	cell	_	_	_	_	_	_	_
44	of	of	_	_	_	_	_	_	_
45	26	26	_	_	_	_	_	_	_
46	patients	patient	_	_	_	_	_	_	_
47	were	be	_	_	_	_	_	_	_
48	examined	examine	_	_	_	_	_	_	_
49	for	for	_	_	_	_	_	_	_
50	c-fos	c-fos	_	_	_	_	_	_	_
51	,	,	_	_	_	_	_	_	_
52	c-myc	c-myc	_	_	_	_	_	_	_
53	,	,	_	_	_	_	_	_	_
54	p53	p53	_	_	_	_	_	_	_
55	and	and	_	_	_	_	_	_	_
56	the	the	_	_	_	_	_	_	_
57	hybrid	hybrid	_	_	_	_	_	_	_
58	bcr/abl	bcr/abl	_	_	_	_	_	_	_
59	mRNA	mrna	_	_	_	_	_	_	_
60	levels	level	_	_	_	_	_	_	_
61	.	.	_	_	_	_	_	_	_

1	Results	result	_	_	_	_	_	_	_
2	indicated	indicate	_	_	_	_	_	_	_
3	that	that	_	_	_	_	_	_	_
4	(	(	_	_	_	_	_	_	_
5	i	i	_	_	_	_	_	_	_
6	)	)	_	_	_	_	_	_	_
7	constitutive	constitutive	_	_	_	_	_	_	_
8	c-fos	c-fos	_	_	_	_	_	_	_
9	transcript	transcript	_	_	_	_	_	_	_
10	levels	level	_	_	_	_	_	_	_
11	are	be	_	_	_	_	_	_	_
12	significantly	significantly	_	_	_	_	_	_	_
13	higher	high	_	_	_	_	_	_	_
14	in	in	_	_	_	_	_	_	_
15	patients	patient	_	_	_	_	_	_	_
16	subsequently	subsequently	_	_	_	_	_	_	_
17	responding	respond	_	_	_	_	_	_	_
18	to	to	_	_	_	_	_	_	_
19	IFN-alpha	IFN-alpha	_	_	_	_	_	_	_
20	therapy	therapy	_	_	_	_	_	_	_
21	(	(	_	_	_	_	_	_	_
22	p	p	_	_	_	_	_	_	_
23	<	<	_	_	_	_	_	_	_
24	0.01	0.01	_	_	_	_	_	_	_
25	)	)	_	_	_	_	_	_	_
26	and	and	_	_	_	_	_	_	_
27	positively	positively	_	_	_	_	_	_	_
28	correlated	correlate	_	_	_	_	_	_	_
29	with	with	_	_	_	_	_	_	_
30	the	the	_	_	_	_	_	_	_
31	proportion	proportion	_	_	_	_	_	_	_
32	of	of	_	_	_	_	_	_	_
33	lymphocytes	lymphocyte	_	_	_	_	_	_	_
34	(	(	_	_	_	_	_	_	_
35	r	r	_	_	_	_	_	_	_
36	=	=	_	_	_	_	_	_	_
37	0.6895	0.6895	_	_	_	_	_	_	_
38	,	,	_	_	_	_	_	_	_
39	p	p	_	_	_	_	_	_	_
40	<	<	_	_	_	_	_	_	_
41	0.01	0.01	_	_	_	_	_	_	_
42	)	)	_	_	_	_	_	_	_
43	and	and	_	_	_	_	_	_	_
44	negatively	negatively	_	_	_	_	_	_	_
45	with	with	_	_	_	_	_	_	_
46	the	the	_	_	_	_	_	_	_
47	proportion	proportion	_	_	_	_	_	_	_
48	of	of	_	_	_	_	_	_	_
49	immature	immature	_	_	_	_	_	_	_
50	cells	cell	_	_	_	_	_	_	_
51	(	(	_	_	_	_	_	_	_
52	r	r	_	_	_	_	_	_	_
53	=	=	_	_	_	_	_	_	_
54	-0.568	-0.568	_	_	_	_	_	_	_
55	,	,	_	_	_	_	_	_	_
56	p	p	_	_	_	_	_	_	_
57	<	<	_	_	_	_	_	_	_
58	0.01	0.01	_	_	_	_	_	_	_
59	)	)	_	_	_	_	_	_	_
60	contained	contain	_	_	_	_	_	_	_
61	in	in	_	_	_	_	_	_	_
62	the	the	_	_	_	_	_	_	_
63	pbmc	pbmc	_	_	_	_	_	_	_
64	preparations	preparation	_	_	_	_	_	_	_
65	tested	test	_	_	_	_	_	_	_
66	,	,	_	_	_	_	_	_	_
67	(	(	_	_	_	_	_	_	_
68	ii	ii	_	_	_	_	_	_	_
69	)	)	_	_	_	_	_	_	_
70	constitutive	constitutive	_	_	_	_	_	_	_
71	mRNA	mrna	_	_	_	_	_	_	_
72	levels	level	_	_	_	_	_	_	_
73	of	of	_	_	_	_	_	_	_
74	the	the	_	_	_	_	_	_	_
75	hybrid	hybrid	_	_	_	_	_	_	_
76	bcr/abl	bcr/abl	_	_	_	_	_	_	_
77	,	,	_	_	_	_	_	_	_
78	c-myc	c-myc	_	_	_	_	_	_	_
79	and	and	_	_	_	_	_	_	_
80	p53	p53	_	_	_	_	_	_	_
81	are	be	_	_	_	_	_	_	_
82	positively	positively	_	_	_	_	_	_	_
83	correlated	correlate	_	_	_	_	_	_	_
84	with	with	_	_	_	_	_	_	_
85	each	each	_	_	_	_	_	_	_
86	other	other	_	_	_	_	_	_	_
87	,	,	_	_	_	_	_	_	_
88	but	but	_	_	_	_	_	_	_
89	failed	fail	_	_	_	_	_	_	_
90	to	to	_	_	_	_	_	_	_
91	relate	relate	_	_	_	_	_	_	_
92	to	to	_	_	_	_	_	_	_
93	disease	disease	_	_	_	_	_	_	_
94	parameters	parameter	_	_	_	_	_	_	_
95	,	,	_	_	_	_	_	_	_
96	and	and	_	_	_	_	_	_	_
97	(	(	_	_	_	_	_	_	_
98	iii	iii	_	_	_	_	_	_	_
99	)	)	_	_	_	_	_	_	_
100	acute	acute	_	_	_	_	_	_	_
101	and	and	_	_	_	_	_	_	_
102	chronic	chronic	_	_	_	_	_	_	_
103	in	in	_	_	_	_	_	_	_
104	vivo	vivo	_	_	_	_	_	_	_
105	exposure	exposure	_	_	_	_	_	_	_
106	to	to	_	_	_	_	_	_	_
107	IFN-alpha	IFN-alpha	_	_	_	_	_	_	_
108	is	be	_	_	_	_	_	_	_
109	accompanied	accompany	_	_	_	_	_	_	_
110	by	by	_	_	_	_	_	_	_
111	upregulation	upregulation	_	_	_	_	_	_	_
112	of	of	_	_	_	_	_	_	_
113	c-fos	c-fos	_	_	_	_	_	_	_
114	and	and	_	_	_	_	_	_	_
115	downregulation	downregulation	_	_	_	_	_	_	_
116	of	of	_	_	_	_	_	_	_
117	c-myc	c-myc	_	_	_	_	_	_	_
118	mRNA	mrna	_	_	_	_	_	_	_
119	levels	level	_	_	_	_	_	_	_
120	in	in	_	_	_	_	_	_	_
121	responder	responder	_	_	_	_	_	_	_
122	patients	patient	_	_	_	_	_	_	_
123	.	.	_	_	_	_	_	_	_

